Rapport Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Rapport Therapeutics, Inc. (RAPP) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- Rapport Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $3.16M, a 26.88% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$814.00K, a 198.67% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $987.00K, a 8125.00% increase year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$2.53M, a 477.08% decline year-over-year.
- Rapport Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $3.60M, a 94.01% increase from fiscal 2024.
- Rapport Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.85M, a 42.06% decline from fiscal 2023.
- Rapport Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $3.20M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.34M 10-Q · filed 2026-08-05 | $3.33M derived: sum of 3 quarters · filed 2026-08-05 | $797.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$814.00K 10-Q · filed 2026-05-07 | $173.00K derived: sum of 2 quarters · filed 2026-05-07 | -$2.36M derived: sum of 3 quarters · filed 2026-05-07 | $1.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $987.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.55M derived: sum of 2 quarters · filed 2026-03-10 | $2.77M derived: sum of 3 quarters · filed 2026-08-05 | $3.60M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.78M derived: sum of 2 quarters · filed 2026-08-05 | $2.61M 10-Q · filed 2025-11-06 | $2.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.14M 10-Q · filed 2026-08-05 | $5.16M derived: sum of 3 quarters · filed 2026-08-05 | $5.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $825.00K 10-Q · filed 2026-05-07 | $837.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.51M derived: sum of 3 quarters · filed 2026-05-07 | $609.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $684.00K derived: sum of 2 quarters · filed 2026-03-10 | -$216.00K derived: sum of 3 quarters · filed 2026-03-10 | $1.85M 10-K · filed 2026-03-10 |
| 2024-09-30 | $672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$228.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.84M 10-Q · filed 2025-11-06 | $3.73M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.17M 10-Q · filed 2025-08-07 | $3.06M derived: sum of 3 quarters · filed 2025-08-07 | $2.55M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.07M 10-Q · filed 2025-05-08 | $3.96M derived: sum of 2 quarters · filed 2025-05-08 | $3.45M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.38M derived: sum of 2 quarters · filed 2025-03-11 | $3.20M 10-K · filed 2025-03-11 | |
| 2023-09-30 | -$508.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.31M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $1.82M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |